NewsRoom Articles - Page 45 of 55

ThursdaySep 29, 2022 9:20 am

Golden Matrix Group Inc. (NASDAQ: GMGI) Rides Growing iGaming Wave with Record-Breaking Revenues, Market Expected to Double by 2027

iGaming market expected to double from $173 billion to over $340 billion by 2027GMGI recently posted record-breaking Q3 revenue results, 16 non-stop profitable quartersGMGI’s industry-standard GM-Ag System provides access to 10,000+ games, simplifies payment options, leverages data analytics to provide total 360-degree performance visibility The iGaming market continues its rapid pace of growth with expectations it will double from $173 billion to over $340 billion by 2027 (https://ibn.fm/8JO3m). Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms and systems, continues to ride the rising wave of industry growth with non-stop consecutive profitable quarters and record-breaking quarterly…

TuesdaySep 27, 2022 10:30 am

Freight Technologies Inc.’s (NASDAQ: FRGT) CFO, Paul Freudenthaler, and President Mike Flinker, Present Company’s Latest Corporate Updates at the H.C. Wainwright 24th Annual Global Investment Conference

Fr8Tech’s August 15, 2022, corporate update formed the backbone for its presentation at the H.C. Wainwright 24th Annual Global Investment Conference held from September 12-14, 2022The company was represented by Paul Freudenthaler and Mike Flinker, who also talked about the company’s role in revolutionizing cross-border shipping, and the role of AI and machine learning in solving current logistical problems in the industry within the NAFTA regionFr8Tech remains committed to exploring new ways to create more value for its clients and streamline the region’s cross-border shipping process, and leveraging technologyJavier Selgas, the company’s CEO, maintains that Fr8Tech anticipates steady long-term growth,…

MondaySep 26, 2022 10:30 am

Cepton, Inc. (NASDAQ: CPTN) Receives Letter of Intent for Up to $100 Million Investment from Strategic Investor; Lidar Technology’s Total Addressable Market Projected to Expand Exponentially

Cepton received a letter of intent from Koito for an investment of up to $100 million to help fund Cepton’s next stage of growth as it scales for mass market deploymentLidar technology within urban settings is becoming increasingly ubiquitous across automotive (i.e., assisted driving & autonomous vehicles) and smart infrastructureSince being the recipient of the largest known ADAS contract from an automotive manufacturer within the lidar space, Cepton maintains a major frontrunner Cepton’s (NASDAQ: CPTN) long-term automotive Tier 1 partner, Koito Manufacturing Co., Ltd. recently revealed that it had provided Cepton with a Letter of Intent representing an investment of…

WednesdaySep 21, 2022 12:45 pm

Flora Growth Corp. (NASDAQ: FLGC) 7x YOY Revenue Growth for H1 2022 Affirms Hyper Growth

H1 2022 revenue increased to ~$15.0 million, up 604% from H1 2021 and 117% from H2 2021, driven by House of BrandsGross Profit increased to ~$7.0 million, up 547% compared to H1 2021 and 363% compared to H2 2021Company reaffirms its 2022 revenue guidance to range between $35.0 million - $45.0 million, indicating approximately 300% - 400% projected revenue growth from 2021 In August, Flora (NASDAQ: FLGC) released its financial and operating results for the six months that ended June 30, 2022 (https://ibn.fm/NjsJi). As an internationally focused cannabis company, the organization’s management acknowledged how challenging the current global cannabis environment…

WednesdaySep 21, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Provide Bioavailable Oral Treatment for Hypertension, Mitigate Effects of High Blood Pressure

Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”)The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controlsLexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of hypertensionThrough pre-clinical studies, DehydraTECH-CBD has been shown to decrease systolic blood pressure among hypertensive volunteersThe company intends to file an Investigational New Drug (“IND”) application and has already received confirmation that the FDA agrees with its proposed abbreviated pathway under section 501(b)(2) Oral delivery remains the preferred…

TuesdaySep 20, 2022 1:30 pm

Freight Technologies Inc. (NASDAQ: FRGT) Using Technology to Help Customers Overcome Challenges of Cross-Border Logistics, Greatly Improving Efficiency

Freight Technologies is a technology company that develops solutions aimed at optimizing and automating the supply chain processThe company’s solutions include Fr8App Platform, Fr8FMS, cloud-based Fr8TMS, Fr8Radar, Fr8Data, and Fr8FleetEarly this year, Freight Technologies unveiled Fr8Fleet, a technology solution for committed capacity planning, and announced it had secured its first contract for this product with Kimberly Clark de Mexico (“KCM”)The company recently reported an expanded relationship with KCM following an agreement to include the Fr8App platform for cross-border logistics for shipments from Mexico to the U.S. An insights report by multinational KPMG, entitled “The challenges of cross-border international trade,” lists…

TuesdaySep 20, 2022 12:45 pm

Flora Growth Corp. (NASDAQ: FLGC) Agreement with Colombian Tribe Strengthens Cannabis Production Supply Chain

Flora Growth is a global cannabis brand-builder focused on the cultivation of product at a central Colombian facility and marketing through a design-led international supply chainFlora recently announced an agreement with Colombia’s Misak tribe for cooperative processing and distribution of cannabis, drawing on the tribe’s licensing advantage to accelerate the pair’s marketing capacityFlora is headquartered in Canada, but its strength lies in its Colombian-based cultivation operations centered in Colombia, one of the largest licensed outdoor operations in the worldIn recent years, Colombia’s government has been working to create a legalization framework for cannabis cultivation, processing and exportation to shake off…

TuesdaySep 20, 2022 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical developmentCybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybinThe high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants were dosed…

TuesdaySep 20, 2022 11:15 am

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organizationQSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populationsCompany creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences (OTCQB: QSAM) is becoming increasingly important. QSAM Biosciences is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “The…

MondaySep 19, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment

Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each yearThe current standard of care for GBM is ineffective for approximately 60% of patientsInitial Phase 1 trial information for Berubicin (approximately 14 years ago) resulted in one patient surviving cancer-free to present and two experiencing significant tumor reduction of up to 80% CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, recently participated in the H.C. Wainwright…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000